Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study

Abstract Introduction The dynamic range of cerebrospinal fluid (CSF) amyloid β (Aβ1–42) measurement does not parallel to cognitive changes in Alzheimer's disease (AD) and cognitively normal (CN) subjects across different studies. Therefore, identifying novel proteins to characterize symptomatic...

Full description

Bibliographic Details
Main Authors: Yuk Yee Leung, Jon B. Toledo, Alexey Nefedov, Robi Polikar, Nandini Raghavan, Sharon X. Xie, Michael Farnum, Tim Schultz, Young Baek, Vivianna M. Van Deerlin, William T. Hu, David M. Holtzman, Anne M. Fagan, Richard J. Perrin, Murray Grossman, Holly D. Soares, Mitchel A. Kling, Matthew Mailman, Steven E. Arnold, Vaibhav A. Narayan, Virginia M‐Y. Lee, Leslie M. Shaw, David Baker, Gayle M. Wittenberg, John Q. Trojanowski, Li‐San Wang, Alzheimer's Disease Neuroimaging Initiative
Format: Article
Language:English
Published: Wiley 2015-09-01
Series:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Subjects:
Cerebrospinal fluid
Biomarkers
Alzheimer's disease
Cognitive impairment
Amyloid beta
Dementia
Online Access:https://doi.org/10.1016/j.dadm.2015.06.008

Internet

https://doi.org/10.1016/j.dadm.2015.06.008

Similar Items